WallStSmart

Jazz Pharmaceuticals PLC (JAZZ)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Jazz Pharmaceuticals PLC generates 598106% more annual revenue ($4.44B vs $742,000). JAZZ leads profitability with a 0.7% profit margin vs 0.0%. JAZZ earns a higher WallStSmart Score of 56/100 (C).

JAZZ

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 0.87

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JAZZUndervalued (+52.2%)

Margin of Safety

+52.2%

Fair Value

$347.46

Current Price

$238.57

$108.89 discount

UndervaluedFair: $347.46Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JAZZ3 strengths · Avg: 8.0/10
PEG RatioValuation
0.968/10

Growing faster than its price suggests

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Revenue GrowthGrowth
19.1%8/10

19.1% revenue growth

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

JAZZ4 concerns · Avg: 3.3/10
EPS GrowthGrowth
3.2%4/10

3.2% earnings growth

Return on EquityProfitability
0.7%3/10

ROE of 0.7% — below average capital efficiency

Profit MarginProfitability
0.7%3/10

0.7% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : JAZZ

The strongest argument for JAZZ centers on PEG Ratio, Operating Margin, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : JAZZ

The primary concerns for JAZZ are EPS Growth, Return on Equity, Profit Margin. A P/E of 1921.3x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

JAZZ profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

JAZZ is growing revenue faster at 19.1% — sustainability is the question.

JAZZ generates stronger free cash flow (389M), providing more financial flexibility.

Bottom Line

JAZZ scores higher overall (56/100 vs 24/100) and 19.1% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Jazz Pharmaceuticals PLC

HEALTHCARE · BIOTECHNOLOGY · USA

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?